Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA, a France-based biopharmaceutical company, is advancing its candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), a condition with no current approved therapies, which positions the company favorably within an unmet medical need segment. Positive clinical outcomes have been observed with lanifibranor improving critical metabolic markers such as HbA1c and triglycerides while demonstrating significant fibrosis improvement in trial metrics, suggesting its potential as a leading therapy in the evolving NASH treatment landscape. Furthermore, collaboration partnerships with AbbVie and BI drive the majority of Inventiva's revenue, reinforcing their financial stability and supporting ongoing research initiatives in key therapeutic areas.

Bears say

Inventiva SA has reported a significant net loss of €175.9 million, or €1.62 per share, highlighting underlying financial challenges that may adversely affect shareholder confidence. The primary clinical program, lanifibranor, is in Phase III development, and any efficacy or safety concerns that arise during this phase could substantially diminish stock performance. Additionally, the company faces multiple risks, including potential clinical trial failures, delays in development timelines, and difficulties accessing equity capital markets, which could further jeopardize its operational viability and financial stability.

Inventiva S.A. (IVA) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 8 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.